海辰药业: 第四届监事会第二十次会议决议公告

Group 1 - The company held a supervisory board meeting where the agenda included the review and approval of certain proposals related to corporate governance and compliance with legal regulations [1][2] - The supervisory board approved a proposal to allow the board's audit committee to exercise the powers of the supervisory board as per the revised Company Law and other relevant regulations, pending approval from the upcoming shareholders' meeting [1][2] - The proposal requires a two-thirds majority vote from shareholders at the 2025 first extraordinary general meeting to be implemented [2] Group 2 - The meeting was conducted through various communication methods, ensuring all members received the necessary materials and information regarding the meeting [1] - The supervisory board will continue to fulfill its responsibilities until the audit committee officially assumes the supervisory board's powers [1] - The company plans to amend its articles of association in conjunction with the establishment of employee representative directors [1]